We finally investigated the prognostic value of the CD4+PD-1+CXCL13+ T cell population in LR-CHL (n = 37) patients uniformly treated with first-line ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)-like treatment. This evidence concerns the gene CXCL13 and classic Hodgkin lymphoma.